Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore the effect of newly added SGLT2I medication or placebo,
to standard medication regimen in diabetic patients with documented stable coronary disease.
Therefore, in the present study the investigators plan to focus on possible anti-inflammatory
and athero-thrombotic protective effects of Dapagliflozin compared to placebo, in secondary
prevention population of stable coronary patients with diabetes. Additionally, the
investigators will explore NT proBNP dynamics, which related to ventricular filling pressures
in this specific population.